Xencor (XNCR) Equity Income (2021)
Xencor (XNCR) posted quarterly Equity Income of $18.3 million for Q2 2021, up 1829900.0% quarter-over-quarter from $1000.0 in Q1 2021.
Powered by 
Analysis
Xencor (XNCR) Equity Income (2021) Analysis & Trends
Xencor (XNCR) has reported Equity Income for 1 consecutive years, with $18.3 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Equity Income changed N/A year-over-year to $18.3 million; the TTM figure through Dec 2021 stood at $18.3 million (changed N/A YoY), while the FY2021 annual figure was $18.3 million, up 2184.77% from the prior year.
- Equity Income climbed to $18.3 million in Q2 2021 per XNCR's latest filing, from $1000.0 in the prior quarter.
- Across five years, Equity Income topped out at $18.3 million in Q2 2021 and bottomed at $1000.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 4.08 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | - |